

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person GROENHUYSEN WILHELMUS CM (Last) (First) (Middle)		2. Issuer Name and Ticker or Trading Symbol NovoCure Ltd [NVCR]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ Chief Financial Officer	
C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300 (Street)		3. Date of Earliest Transaction (MM/DD/YYYY) 11/11/2019		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	
MALVERN, PA 19355 (City) (State) (Zip)		4. If Amendment, Date Original Filed (MM/DD/YYYY)			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	3A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares	11/11/2019		M		1900	A	\$3.44	89079	D	
Ordinary Shares	11/11/2019		S		1900	D	\$80.145	87179	D	
Ordinary Shares	11/11/2019		M		4800	A	\$3.44	91979	D	
Ordinary Shares	11/11/2019		S		4800	D	\$80.119	87179	D	
Ordinary Shares	11/11/2019		M		1900	A	\$7.03	89079	D	
Ordinary Shares	11/11/2019		S		1900	D	\$80.141	87179	D	
Ordinary Shares	11/12/2019		M		10000	A	\$3.44	97179	D	
Ordinary Shares	11/12/2019		S		10000	D	\$80.302	87179	D	
Ordinary Shares	11/12/2019		M		20000	A	\$3.44	107179	D	
Ordinary Shares	11/12/2019		S		20000	D	\$80.187	87179	D	
Ordinary Shares	11/12/2019		M		10000	A	\$7.03	97179	D	
Ordinary Shares	11/12/2019		S		10000	D	\$80.005	87179	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					
Options to Buy Ordinary Shares	\$3.44	11/11/2019		M		1900	(S)	12/13/2021	Ordinary Shares	1900.0	\$0	25169	D
Options to Buy Ordinary Shares	\$3.44	11/11/2019		M		4800	(S)	12/13/2021	Ordinary Shares	4800.0	\$0	85832	D
Options to Buy Ordinary Shares	\$7.03	11/11/2019		M		1900	(S)	2/19/2023	Ordinary Shares	1900.0	\$0	56386	D
Options to Buy Ordinary Shares	\$3.44	11/12/2019		M		10000	(S)	12/13/2021	Ordinary Shares	10000.0	\$0	15169	D
Options to Buy Ordinary Shares	\$3.44	11/12/2019		M		20000	(S)	12/13/2021	Ordinary Shares	20000.0	\$0	65832	D
Options to Buy Ordinary Shares	\$7.03	11/12/2019		M		10000	(S)	2/19/2023	Ordinary Shares	10000.0	\$0	46386	D

Explanation of Responses:

- On November 11, 2019, Mr. Groenhuisen sold 1,900 shares in multiple trades at prices ranging from \$80.00 to \$80.38. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
- On November 11, 2019, Mr. Groenhuisen sold 4,800 shares in multiple trades at prices ranging from \$80.00 to \$80.27. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
- On November 12, 2019, Mr. Groenhuisen sold 10,000 shares in multiple trades at prices ranging from \$80.00 to \$80.85. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
- On November 12, 2019, Mr. Groenhuisen sold 20,000 shares in multiple trades at prices ranging from \$80.00 to \$80.22. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
- On November 12, 2019, Mr. Groenhuisen sold 10,000 shares in multiple trades at prices ranging from \$80.00 to \$80.09. The price reported above reflects the weighted average sale price. Mr. Groenhuisen hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected.
- Options exercised were fully vested as of the date hereof.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
GROENHUYSEN WILHELMUS CM C/O NOVOCURE INC., 20 VALLEY STREAM PARKWAY, SUITE 300 MALVERN, PA 19355			Chief Financial Officer	

Signatures

By: /s/ Todd Longworth, Attorney in Fact for Wilhelmus CM Groenhuisen 11/13/2019
Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

LIMITED POWER OF ATTORNEY FOR
SECTION 16 REPORTING PURPOSES

Know all by these presents, that the undersigned hereby makes, constitutes and appoints Todd Longworth, Kimberly Burke and Carrie Kane, acting individually, as the undersigned's true and lawful attorneys-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

(1) execute for, and on behalf of, the undersigned, in the undersigned's capacity as an officer, director and/or 10% beneficial owner of Novocure Limited (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder (the "Exchange Act");

(2) seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to any attorneys-in-fact and further approves and ratifies any such release of information;

(3) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare, complete and execute any such Form 3, 4 or 5, and any amendments thereto, or other required report and timely file such Forms or reports with the United States Securities and Exchange Commission, the New York Stock Exchange and any stock exchange or similar authority as considered necessary or advisable under Section 16(a) of the Exchange Act; and

(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorneys-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorneys-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such terms and conditions as such attorneys-in-fact may approve in such attorney-in-fact's sole discretion.

The undersigned hereby gives and grants to each such attorneys-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneys-in-fact, or such attorneys-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.

The undersigned hereby acknowledges that (a) the foregoing attorneys-in-fact are serving in such capacity at the request of the undersigned; (b) this Limited Power of Attorney authorizes, but does not require, each such attorneys-in-fact to act in his or her discretion on information provided to such attorneys-in-fact without independent verification of such information; (c) any documents prepared and/or executed by any attorneys-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney shall be in such form and shall contain such information and disclosure as such attorneys-in-fact, in his or her sole discretion, deems necessary or advisable; (d) neither the Company nor any attorneys-in-fact assumes (i) any liability for the undersigned's responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and (e) this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned's obligations under the Exchange Act, including, without limitation, the reporting requirements under Section 16 of the Exchange Act.

This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked as to any attorneys-in-fact by the undersigned in a signed writing delivered to such attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of September, 2016.

____ By: /s/ Wilco Groenhuysen____
Signature

____ Wilco Groenhuysen____
Print Name